We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App





New Method Tested for Early Diagnosis Pediatric Diabetic Nephropathy

By LabMedica International staff writers
Posted on 04 Aug 2016
Print article
Image: A histopathology of nodular glomerulosclerosis in the kidney of a patient with diabetic nephropathy (Photo courtesy of the CDC).
Image: A histopathology of nodular glomerulosclerosis in the kidney of a patient with diabetic nephropathy (Photo courtesy of the CDC).
In type 1 diabetic patients who have progressed to the final stages of nephropathy, kidney failure eventually develops in 50% of individuals within 10 years after the onset of overt nephropathy and in greater than 75% by the 20-year mark.

Nephropathy is diagnosed through the detection of increased urinary albumin excretion, but a growing body of evidence suggests that the risk for developing diabetic nephropathy starts when urinary albumin excretion levels are still within the normal range. If the onset of nephropathy could be detected before urinary albumin rises, patients could potentially be placed on treatment to prevent its development.

A team of scientists at the Aghia Sophia Children’s Hospital (Athens, Greece) has determined that two proteins, growth differentiation factor-15 (GDF-15) and chitinase-3-like protein 1 (YKL-40), could be used to detect diabetic nephropathy early. The team tested 56 type 1 diabetes patients mean age 13.1 ± 3.2 years and 49 healthy controls ages 12.8 ± 6.6 years, for GDF-15 and YKL-40 which were performed by means of immunoenzymatic and immunonephelometric techniques at time of enrollment in the study and after 12 to15 months. Also at these two time points, they evaluated subjects’ kidney function by measuring cystatin C to determine estimated glomerular filtration rate (eGFR) and measuring neutrophil gelatinase associated lipocalin (NGAL).

The teams found that after 12 to 15 months, GDF-15 levels in diabetes patients were significantly higher at 366.7 pg/mL than in healthy controls at 278.6 pg/mL. Initially, no significant difference in YKL-40 measurements was observed between diabetes patients and controls at time of enrollment, but over the course of the study, mean YKL-40 levels in diabetes patients proceeded to increase from 17.4 ng/mL to 20.5 ng/mL. GDF-15 levels also correlated negatively with eGFR values, while YKL-40 levels correlated positively with NGAL and GDF-15, indicating that rises in both proteins reflect a decline in kidney function.

Ioannis Papassotiriou, PhD, the team leader, said, “This is the first study to demonstrate a predictive role for serum GDF-15 and YKL-40 as early markers of diabetic nephropathy in children and adolescents with type 1 diabetes before severe overt nephropathy occurs. Defining new predictors as supplementary tests to urinary albumin excretion for the early diagnosis of diabetic nephropathy could accelerate effective management and treatment approaches needed to minimize the rates of severe renal morbidity and mortality in young patients with type 1 diabetes.”

Related Links:
Aghia Sophia Children’s Hospital

Automated ELISA-IFA-BLOT Processor AP 22
Gold Supplier
ESR Analyzer
miniiSED™
New
Vertical Autoclaves
60L-150L Top-Loading Autoclaves
New
Integrated Chemistry & Immunoassay System
Dimension RxL Max

Print article

Channels

Molecular Diagnostics

view channel
Image: A new machine rapidly and robustly separates cancer cells from blood samples (Photo courtesy of DGIST)

Centrifugal System for Separating Circulating Tumor Cells from Blood Samples to Improve Cancer Diagnosis

Circulating tumor cells are cells that break off from cancers and are released into the blood stream. They can go on to form the seeds for new tumor formation in other parts of the body, known as metastases.... Read more

Industry

view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.